Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

This is read by an automated voice. Please report any issues or inconsistencies here. After decades of public and self-imposed shame, Oprah credits a GLP-1 drug with silencing “food noise” — the ...

Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through the courts. Thousands of patients have filed lawsuits claiming the makers of ...

A new weight loss pill has shown promise as a more convenient medication for adults with obesity and type 2 diabetes. The once-daily pill appears to be effective and safe for these patients, according ...

This article originally appeared on PolitiFact. If you watch TV and don't mute ads, you've probably heard of a few biologics. They're drugs such as Humira for arthritis and Trulicity for Type 2 ...

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...

HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...

President Donald Trump on Thursday announced deals with pharmaceutical giants Novo Nordisk and Eli Lilly that would cut the cost of the lowest doses of their in-demand weight-loss drugs, lowering the ...

Medicare will begin covering weight loss drugs in 2026 for the first time under a pricing agreement announced by the White House, according to a Nov. 6 press release. The agreements with Eli Lilly and ...